Shine Investment Advisory Services’s Sarepta Therapeutics SRPT Stock Holding History

Shine Investment Advisory Services’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$22K	Hold	154	–	–	0.01%	437
2020 Q2	$25K	Hold	154	–	–	0.01%	428
2020 Q1	$15K	Buy	154 +28	+22%	+$3.2K	0.01%	465
2019 Q4	$16K	Buy	126 +6	+5%	+$606	0.01%	507
2019 Q3	$9K	Buy	120 +88	+275%	+$10.4K	﹤0.01%	577
2019 Q2	$5K	Hold	32	–	–	﹤0.01%	623
2019 Q1	$4K	Hold	32	–	–	﹤0.01%	646
2018 Q4	$3K	Hold	32	–	–	﹤0.01%	644
2018 Q3	$5K	Buy	+32	New	+$4.37K	﹤0.01%	606

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Shine Investment Advisory Services's SRPT Position: Q3 2020 in Review

Shine Investment Advisory Services held its Sarepta Therapeutics (SRPT) position steady in Q3 2020 at 154 shares worth $22K. The position accounts for 0.01% of the portfolio, ranked #437.

Shine Investment Advisory Services first reported a position in SRPT in Q3 2018 and has held it in 9 quarters since. The position peaked at $25K in Q2 2020. 404 funds tracked by Wall St. Rank hold SRPT as of Q3 2020.

Shine Investment Advisory Services held 154 shares of Sarepta Therapeutics worth $22K as of Q3 2020.
Shine Investment Advisory Services left its Sarepta Therapeutics share count unchanged in Q3 2020.
Sarepta Therapeutics made up 0.01% of Shine Investment Advisory Services's portfolio in Q3 2020, its #437 holding.
Shine Investment Advisory Services first reported a position in Sarepta Therapeutics in Q3 2018 and has held it in 9 quarters since.
Shine Investment Advisory Services's Sarepta Therapeutics position peaked at $25K in Q2 2020.
404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2020.

Based on Shine Investment Advisory Services's 13F filing for Q3 2020, filed 3 Nov 2020.